Sobi Ramps Up In Rare Diseases With Apellis Deal

$250m Upfront Fee For Rights To Pegcetacoplan

 
• By Kevin Grogan
US dollars
Sobi spending big to boost portfolio • Source: Archive

More from Rare Diseases

More from Scrip